Flumazenil
Clinical data | |
---|---|
Trade names | Anexate, Lanexat, Mazicon, Romazicon |
Other names | ethyl 8-fluoro- 5,6-dihydro- 5-methyl- 6-oxo- 4H- imidazo [1,5-a] [1,4] benzodiazepine- 3-carboxylate |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 7–15 min (initial) 20–30 min (brain) 40–80 min (terminal) |
Excretion | Urine 90–95% Feces 5–10% |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Flumazenil (also known as flumazepil, code name Ro 15-1788[3]) is a selective GABAA receptor antagonist[4] administered via injection, otic insertion, or intranasally. Therapeutically, it acts as both an antagonist and antidote to benzodiazepines (particularly in cases of overdose), through competitive inhibition.
It was first characterized in 1981,
Medical uses
Flumazenil benefits patients who become excessively drowsy after use of
The drug has been used as an
Flumazenil is also sometimes used after surgery to reverse the sedative effects of benzodiazepines. This is similar to
Flumazenil has been effectively used to treat overdoses of non-benzodiazepine hypnotics, such as zolpidem, zaleplon and zopiclone (also known as "Z-drugs").[9]
It may also be effective in reducing
The drug has also been used in hepatic encephalopathy. It may have beneficial short‐term effects in people with cirrhosis, but there is no evidence for long-term benefits.[10]
The onset of action is rapid, and effects are usually seen within one to two minutes. The peak effect is seen at six to ten minutes. The recommended dose for adults is 200 μg every 1–2 minutes until the effect is seen, up to a maximum of 3 mg per hour. It is available as a clear, colourless solution for
Many benzodiazepines (including
It is hepatically metabolised to inactive compounds which are excreted in the urine. Individuals who are physically dependent on benzodiazepines may experience
It is not recommended for routine use in those with a decreased
In terms of drug enforcement initiatives, diversion control programs and required post-marketing surveillance of adverse events, orders for flumazenil may trigger a prescription audit to the search for benzodiazepine misuse and for clinically significant adverse reactions related to their use.[13]
PET radioligand
Radiolabeled with the radioactive isotope
Treatment for benzodiazepine dependence & tolerance
Epileptic patients who have become tolerant to the anti-seizure effects of the benzodiazepine clonazepam became seizure-free for several days after treatment with 1.5 mg of flumazenil.[15] Similarly, patients who were dependent on high doses of benzodiazepines (median dosage 333 mg diazepam-equivalent) were able to be stabilised on a low dose of clonazepam after 7–8 days of treatment with flumazenil.[16]
Flumazenil has been tested against placebo in benzodiazepine-dependent subjects. Results showed that typical benzodiazepine withdrawal effects were reversed with few to no symptoms.[17] Flumazenil was also shown to produce significantly fewer withdrawal symptoms than saline in a randomized, placebo-controlled study with benzodiazepine-dependent subjects. Additionally, relapse rates were much lower during subsequent follow-up.[18]
In vitro studies of tissue cultured cell lines have shown that chronic treatment with flumazenil enhanced the benzodiazepine binding site where such receptors have become more numerous and uncoupling/down-regulation of GABAA has been reversed.[19][20][21] After long-term exposure to benzodiazepines, GABAA receptors become down-regulated and uncoupled. Growth of new receptors and recoupling after prolonged flumazenil exposure has also been observed. It is thought this may be due to increased synthesis of receptor proteins.[22]
Flumazenil was found to be more effective than placebo in reducing feelings of hostility and aggression in patients who had been free of benzodiazepines for 4–266 weeks.[23] This may suggest a role for flumazenil in treating protracted benzodiazepine withdrawal symptoms.
Low-dose, slow
In Italy, the gold standard for treatment of high-dose benzodiazepine dependency is 8–10 days of low-dose, slowly infused flumazenil.[26] One addiction treatment centre in Italy has used flumazenil to treat over 300 patients who were dependent on high doses of benzodiazepines (up to 70 times higher than conventionally prescribed) with physicians being among the clinic's most common patients.[27]
Pharmacology
Flumazenil, an imidazobenzodiazepine derivative, antagonizes the actions of benzodiazepines on the central nervous system. Flumazenil competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex.[28] It also exhibits weak partial agonism of GABAA receptor complexes that contain α6-type monomers; the clinical relevance of this is unknown.[29]
Flumazenil does not antagonize all of the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, and most anesthetics) and does not reverse the effects of opioids. It will however antagonize the action of non-benzodiazepine
Pharmacodynamics
Intravenous flumazenil has been shown to antagonize sedation, impairment of recall, psychomotor impairment and ventilatory depression produced by benzodiazepines in healthy human volunteers.
The duration and degree of reversal of sedative benzodiazepine effects are related to the dose and plasma concentrations of flumazenil.
Availability
Flumazenil is sold under a wide variety of brand names worldwide like Anexate, Lanexat, Mazicon, Romazicon. In India it is manufactured by Roche Bangladesh Pharmaceuticals and USAN Pharmaceuticals.[citation needed]
See also
References
- FDA. Retrieved 22 Oct 2023.
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- S2CID 4340263.
- S2CID 24494744.
- PMID 2903780.
- ^ S2CID 44236050.
- ^ Clinical trial number NCT01183312 for "Flumazenil for the Treatment of Primary Hypersomnia" at ClinicalTrials.gov
- ^ ISBN 978-0-07-136001-2.
- ISBN 978-0-07-147914-1.
- PMID 28796283.
- ISBN 978-1-264-25807-9.
- ISBN 978-0-07-141640-5.
- S2CID 12973546.
- PMID 12764053.
- S2CID 41180892.
- S2CID 28979824.
- PMID 8803645.
- S2CID 21255719.
- PMID 16084060.
- PMID 15659288.
- PMID 15531382.
- S2CID 9033302.
- S2CID 41351863.
- S2CID 27167585.
- S2CID 42432213.
- PMID 21320225.
- PMID 22509854.
- PMID 23126253.
- PMID 8632757.
- ^ PMID 23404347.
- S2CID 34655918.
- S2CID 34525063.
External links
- Media related to Flumazenil at Wikimedia Commons
- Flumazenil drug label/data at DailyMed from U.S. National Library of Medicine, National Institutes of Health.
- Romazicon product information, Roche USA